One thing that stands out about Recursion right away is how the company refers to itself. Recursion doesn't say that it's a pharmaceutical, biopharmaceutical, or biotech company. Instead, it uses the ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Thinking about what to do with Recursion Pharmaceuticals stock right now? You are not alone. In just the past week, the stock has jumped an impressive 19.2%, adding to an 18.5% surge over 30 days. It ...

Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Pinker's new book reveals how recursive mentalizing—thinking about thinking—may be the hidden engine of human life, from ...

Recursion Pharmaceuticals RXRX stock surged 16% in early October 2025 on renewed AI interest despite posting $171.9 million ...

Recursion Pharmaceuticals jumped by 16.44 percent on Wednesday to close at $6.09 apiece as investors repositioned portfolios ahead of expected updates from an upcoming AI conference in Dubai.